- Home
- BCDA vs SILO Comparison
BCDA vs SILO Comparison
Compare BCDA & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SILO
- Stock Information
- Founded
- BCDA N/A
- SILO 2010
- Country
- BCDA United States
- SILO United States
- Employees
- BCDA N/A
- SILO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- BCDA Health Care
- SILO Consumer Discretionary
- Exchange
- BCDA Nasdaq
- SILO Nasdaq
- Market Cap
- BCDA 9.4M
- SILO 8.8M
- IPO Year
- BCDA N/A
- SILO N/A
- Fundamental
- Price
- BCDA $2.57
- SILO $1.32
- Analyst Decision
- BCDA Strong Buy
- SILO
- Analyst Count
- BCDA 1
- SILO 0
- Target Price
- BCDA $25.00
- SILO N/A
- AVG Volume (30 Days)
- BCDA 52.1K
- SILO 116.2K
- Earning Date
- BCDA 03-26-2025
- SILO 03-18-2025
- Dividend Yield
- BCDA N/A
- SILO N/A
- EPS Growth
- BCDA N/A
- SILO N/A
- EPS
- BCDA N/A
- SILO N/A
- Revenue
- BCDA $71,000.00
- SILO $72,102.00
- Revenue This Year
- BCDA N/A
- SILO $1.86
- Revenue Next Year
- BCDA N/A
- SILO N/A
- P/E Ratio
- BCDA N/A
- SILO N/A
- Revenue Growth
- BCDA N/A
- SILO N/A
- 52 Week Low
- BCDA $1.63
- SILO $0.77
- 52 Week High
- BCDA $6.45
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- BCDA 56.03
- SILO 45.03
- Support Level
- BCDA $2.50
- SILO $1.21
- Resistance Level
- BCDA $2.71
- SILO $1.34
- Average True Range (ATR)
- BCDA 0.23
- SILO 0.11
- MACD
- BCDA 0.02
- SILO 0.00
- Stochastic Oscillator
- BCDA 81.01
- SILO 41.38
Stock Price Comparison Chart: BCDA vs SILO
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.